ClinicalTrials.gg
TerminatedNCT04320940Updated Oct 26, 2023Results posted

Efficacy and Safety of Intravenous Phenobarbital in Neonatal Seizures

A Phase 3 interventional study of Phenobarbital Sodium Injection in Epilepsy, Benign Neonatal, sponsored by NEMA Research, Inc.. Terminated at 8 sites in 2 countries. Open to participants aged 34 Weeks to 44 Weeks. Per ClinicalTrials.gov, last updated 2023-10-26.

Sponsored by NEMA Research, Inc. · Phase 3, Interventional, and Treatment

Why this study was terminated
Insufficient participant recruitment hindered the study's progress, preventing robust data collection and compromising statistical power

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4
Allocation
Randomized
Ages
34 Weeks to 44 Weeks
Sex
All
01

Study summary

This is a randomized, double-blind, parallel-group, Phase 3 study to evaluate the efficacy of the administration of phenobarbital sodium injection in neonates who have suffered from electrographic or electroclinical seizure. As neonatal seizures can have long-term adverse effects, including death, placebo-controlled studies are not appropriate for this population. This study is designed to show intravenous phenobarbital is effective at preventing subsequent seizures by demonstrating greater efficacy at a higher dose compared to a lower dose.

02

Conditions studied

  • Epilepsy, Benign Neonatal

Keywords

  • Neonatal Seizures
  • Phenobarbital
  • Anticonvulsants
03

In context

Lead sponsor

NEMA Research, Inc. is the lead sponsor of 15 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
34 Weeks to 44 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female neonates with a gestational age of ≥ 34 - ≤44 weeks admitted into the NICU with a high probability of developing seizures (e.g., HIE, stroke, intracerebral hemorrhage, central nervous system infection)
  • Parental (in-person or remote consent)
  • Undergoing continuous video electroencephalogram (cvEEG) monitoring
  • Has evidence of electrographic seizure burden of at least 30 seconds/h

Exclusion criteria

Exclusion Criteria:

  • Received anticonvulsant treatment, including phenobarbital, prior to randomization (with exception of lorazepam administered for sedation > 24 hours before enrollment)
  • Strong suspicion or confirmed diagnosis of brain malformation, inborn error of metabolism genetic syndrome, or major congenial malformation prior to randomization
  • Seizures responding to correction of hypoglycemia, hypocalcemia or any other metabolic disorder
  • Death appears to be imminent as assessed by the NICU attending physician
  • Is currently enrolled in another study assessing the same and/or similar primary/secondary endpoints with/without drug treatment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
4 participants (actual)

Study arms

  • Active comparator
    Phenobarbital Sodium Injection 20mg

    Following confirmation of seizure criteria and randomization, subjects will receive Phenobarbital 20 mg/kg (first/initial dose) followed by 20 mg/kg (if required).

    Drug: Phenobarbital Sodium Injection

  • Active comparator
    Phenobarbital Sodium Injection 40mg

    Following confirmation of seizure criteria and randomization, subjects will receive Phenobarbital 40 mg/kg (first/initial dose) followed by 10 mg/kg (if required).

    Drug: Phenobarbital Sodium Injection

Interventions

  • The initial dose will be administered intravenously over a 30-minute period. The time period between the first and second dose of phenobarbital cannot occur within 30 minutes of the end of the first dose.

    Also known as: Phenobarbital

06

What researchers measure

Primary outcomes

  1. Neonates Who do Not Require Additional Seizure Treatment After the First Dose of Phenobarbital.

    Percent of neonates who do not require additional seizure treatment after the first dose of phenobarbital during the first 24 hours after treatment.

    Time frame: 24 hours

Secondary outcomes

  1. Neonates Who do Not Require Additional Seizure Treatment After the First Dose of Phenobarbital.

    Percent of neonates who do not require additional seizure treatment after 2 hours of the first dose of phenobarbital.

    Time frame: 2 hours

  2. Neonates Who do Not Require Additional Seizure Treatment After the Second Dose of Phenobarbital.

    Percent of neonates who do not require additional seizure treatment after the second dose of phenobarbital within the first 24 hours of treatment.

    Time frame: 24 hours

  3. Seizure Burden Over 48 Hours Following Initial Administration of the Phenobarbital Injection.

    Number of subject required monitoring of seizure burden over 48 hours following initial administration of the phenobarbital injection.

    Time frame: 48 hours

07

Results

Posted Oct 26, 2023

Participant flow

Participant flow — Overall Study
MilestonePhenobarbital Sodium Injection 20mgPhenobarbital Sodium Injection 40mg
Started31
Completed31
Not completed00

Outcome measures

PrimaryNeonates Who do Not Require Additional Seizure Treatment After the First Dose of Phenobarbital.

Percent of neonates who do not require additional seizure treatment after the first dose of phenobarbital during the first 24 hours after treatment.

Time frame:
24 hours
Reported as:
Count of participants · Participants
Neonates Who do Not Require Additional Seizure Treatment After the First Dose of Phenobarbital.
ParticipantsPhenobarbital Sodium Injection 20mgPhenobarbital Sodium Injection 40mg
Neonates Who do Not Require Additional Seizure Treatment After the First Dose of Phenobarbital.21
SecondaryNeonates Who do Not Require Additional Seizure Treatment After the First Dose of Phenobarbital.

Percent of neonates who do not require additional seizure treatment after 2 hours of the first dose of phenobarbital.

Time frame:
2 hours
Reported as:
Count of participants · Participants
Neonates Who do Not Require Additional Seizure Treatment After the First Dose of Phenobarbital.
ParticipantsPhenobarbital Sodium Injection 20mgPhenobarbital Sodium Injection 40mg
Neonates Who do Not Require Additional Seizure Treatment After the First Dose of Phenobarbital.21
SecondaryNeonates Who do Not Require Additional Seizure Treatment After the Second Dose of Phenobarbital.

Percent of neonates who do not require additional seizure treatment after the second dose of phenobarbital within the first 24 hours of treatment.

Time frame:
24 hours
Reported as:
Count of participants · Participants
Neonates Who do Not Require Additional Seizure Treatment After the Second Dose of Phenobarbital.
ParticipantsPhenobarbital Sodium Injection 20mgPhenobarbital Sodium Injection 40mg
Neonates Who do Not Require Additional Seizure Treatment After the Second Dose of Phenobarbital.10
SecondarySeizure Burden Over 48 Hours Following Initial Administration of the Phenobarbital Injection.

Number of subject required monitoring of seizure burden over 48 hours following initial administration of the phenobarbital injection.

Time frame:
48 hours
Reported as:
Count of participants · Participants
Seizure Burden Over 48 Hours Following Initial Administration of the Phenobarbital Injection.
ParticipantsPhenobarbital Sodium Injection 20mgPhenobarbital Sodium Injection 40mg
Seizure Burden Over 48 Hours Following Initial Administration of the Phenobarbital Injection.10

Adverse events

Collected over All-Cause Mortality and Serious Adverse Events were assessed up to 30 days following the first treatment, on average 45 days. Other (Not Including Serious) Adverse Events were assessed for up to 24 hours following the first treatment and up to 4 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phenobarbital Sodium Injection 20mg0/3 (0%)1/3 (33.3%)0/3 (0%)
Phenobarbital Sodium Injection 40mg0/1 (0%)0/1 (0%)0/1 (0%)
Most frequent serious events
Most frequent serious events
EventPhenobarbital Sodium Injection 20mgPhenobarbital Sodium Injection 40mg
pulmonary hypertensionRespiratory, thoracic and mediastinal disorders1/30/1

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Phenobarbital Sodium Injection 20mgPhenobarbital Sodium Injection 40mgTotal
<=18 years314
Between 18 and 65 years000
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Phenobarbital Sodium Injection 20mgPhenobarbital Sodium Injection 40mgTotal
Female101
Male213
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phenobarbital Sodium Injection 20mgPhenobarbital Sodium Injection 40mgTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American011
White303
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Phenobarbital Sodium Injection 20mgPhenobarbital Sodium Injection 40mgTotal
United States314
08

Study locations

8 sites
  • Arkansas Cildren's Hospital
    Little Rock, Arkansas 72202, United States
  • Children's National Hospital
    Washington, District of Columbia 20010, United States
  • South Miami Hospital
    Miami, Florida 33143, United States
  • Jamie Flores-Torres
    Tampa, Florida 33606, United States
  • Matthew Butoryak
    Pittsburgh, Pennsylvania 15213, United States
  • UPMC Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15224, United States
  • Marshall Health
    Huntington, West Virginia 25701, United States
  • Jordan University of Science and Technology (King Abdullah University Hospital, KAUH)
    Irbid', 22110, Jordan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — There is no plan to share IPD.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Feb 2023, 22 months.

Results were first posted in Oct 2023, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2020
First posted
Mar 25, 2020
StartActual
Mar 12, 2021
Primary completionActual
Feb 1, 2023
CompletionActual
Feb 1, 2023
Results first posted
Oct 26, 2023
Last update
Oct 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04320940
Lead sponsor
NEMA Research, Inc.
Responsible party
Sponsor
First posted
Mar 25, 2020
Start date
Mar 12, 2021
Primary completion
Feb 1, 2023
Completion
Feb 1, 2023
Results posted
Oct 26, 2023
Last update
Oct 26, 2023

Study contacts

Joseph Pergolizzi Jr., MD, MD
principal investigator · NEMA Research, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Phenobarbital

Start the discussion